Steven Blotner
- Hepatology top 5%
- Hepatitis C virus research 6
- Oncology top 5%
- Cancer-related Molecular Pathways 9
- Cancer Research top 10%
- Hematology top 10%
- Acute Myeloid Leukemia Research 5
- Pathology and Forensic Medicine top 10%
-
- HIV/AIDS drug development and treatment 13
-
- Retinal Diseases and Treatments 6
-
- Retinal Imaging and Analysis 5
-
- DNA Repair Mechanisms 4
-
- Chronic Lymphocytic Leukemia Research 4
- Co-authors
- Howard A. BurrisChristopher J. SweeneyKatja SchulzeFunda Meric‐BernstamVaikunth CuchelkarDavid R. SpigelJohn D. HainsworthRon Bose
- Cited by
- HepatologyOncologyCancer Research
- Journals
- Journal of Clinical Oncology (4 papers)Investigational New Drugs (3 papers)Cancer Chemotherapy and Pharmacology (3 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Steven Blotner
34 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 76
- Hepatology 178
- Oncology 598
- Cancer Research 177
- Hematology 118
- Pathology and Forensic Medicine 175
Countries citing papers authored by Steven Blotner
This map shows the geographic impact of Steven Blotner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Blotner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Blotner more than expected).
Fields of papers citing papers by Steven Blotner
This network shows the impact of papers produced by Steven Blotner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Blotner. The network helps show where Steven Blotner may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Steven Blotner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2022 | 12 | |
| 4 | 2022 | 2 | |
| 5 | Clinical trial versus real-world outcomes with anti-VEGF therapy for branch and central retinal vein occlusion | 2020 | 0 |
| 6 | Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD: End of Study Results | 2020 | 1 |
| 7 | 2020 | 16 | |
| 8 | 2020 | 79 | |
| 9 | Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studybreakdown → | 2019 | 383 |
| 10 | 2019 | 14 | |
| 11 | 2019 | 13 | |
| 12 | 2018 | 16 | |
| 13 | 2018 | 12 | |
| 14 | 2013 | 34 | |
| 15 | 2012 | 16 | |
| 16 | 2007 | 13 | |
| 17 | 2006 | 34 | |
| 18 | 2001 | 19 | |
| 19 | 2000 | 22 | |
| 20 | 1993 | 74 |
About Steven Blotner
Steven Blotner is a scholar working on Hepatology, Infectious Diseases and Ophthalmology, having authored 36 papers that have together received 1.1k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (13 papers), Cancer-related Molecular Pathways (9 papers), Retinal Diseases and Treatments (6 papers), Hepatitis C virus research (6 papers), Acute Myeloid Leukemia Research (5 papers), Retinal Imaging and Analysis (5 papers), DNA Repair Mechanisms (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Hepatology (178 citations), Oncology (598 citations) and Cancer Research (177 citations). Steven Blotner has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Howard A. Burris, Christopher J. Sweeney, Katja Schulze, Funda Meric‐Bernstam, Vaikunth Cuchelkar, David R. Spigel, John D. Hainsworth, Ron Bose, Razelle Kurzrock and Charles Swanton. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Cancer Chemotherapy and Pharmacology, Blood and Ophthalmology Retina.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.